Expert Commentary

Female sexual dysfunction: Is pharmacologic treatment a future reality or just wishful thinking?

OBG Manag. 2014 October;26(10)
By
Jan Shifren, MD
Author and Disclosure Information

Jan Shifren, MD, discusses in which patients pharmacologic treatment is appropriate, which pharmacologic treatments are actual management options, and her ideal management approach for a patient with female sexual dysfunction

 

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

After 3-year stumble, new weight-loss drug wins FDA approval
MDedge ObGyn
Conjugated estrogen plus bazedoxifene—a new approach to estrogen therapy
MDedge ObGyn
Ideal patient selection for this new approach to HT
MDedge ObGyn
New mobile app assists clinicians in assessing menopausal patients
MDedge ObGyn
MenoPro: An app from NAMS for you and your menopausal patient
MDedge ObGyn
PODCAST: Alternatives to hormone therapy exist for women with moderate to severe menopause symptoms
MDedge ObGyn
VIDEO: Is the FDA’s black box on estrogen too ‘alarming’?
MDedge ObGyn
AUDIO: Conjugated estrogen, bazedoxifene combo offers menopause treatment option
MDedge ObGyn
VIDEO: Causes of low libido in postmenopausal women are complex, don’t always require pharmacologic treatment
MDedge ObGyn
VIDEO: Novel and other therapies for vaginal dryness
MDedge ObGyn

Related Articles